|

Cabozantinib Clinical Trials

43 actively recruiting trials across 24 locations

▼ -1 trial since May 2026

Also known as: 177Lu-PSMA-617, BMS907351, CABOMETYX, CABOMETYX®, COMETRIQ +8 more

Pipeline

Early 1: 1Phase 1: 6Phase 2: 23Phase 3: 5Phase 4: 1Phase 1/2: 6

Top Sponsors

  • M.D. Anderson Cancer Center4
  • National Cancer Institute (NCI)3
  • Merck Sharp & Dohme LLC2
  • Memorial Sloan Kettering Cancer Center2
  • Gustave Roussy, Cancer Campus, Grand Paris2

Indications

Other11 trials

A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)
Phase 3
A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors.
Phase 2
CARE1 Pragmatic Clinical Trial
Phase 3
Cabozantinib Dose Skipping as an Alternative to Dose Reductions
Phase 2
Cabozantinib and Lanreotide as Treatment for Gastroenteropancreatic Neuroendocrine Tumors
Phase 1/2
Cabozantinib and Nivolumab Among Older Patients With Renal Cell Carcinoma
Phase 4
Cabozantinib to Treat Recurrent Liver Cancer Post Transplant
Phase 2
Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer
Phase 2
Immune Checkpoint Therapy vs Target Therapy in Reducing Serum HBsAg Levels in Patients With HBsAg+ Advanced Stage HCC
Phase 2
Retrospective Analysis of Patients With Metastatic Renal Cell Carcinoma Treated With CABOzantinib
The Drug Rediscovery Protocol (DRUP Trial)
Phase 2

Birmingham, Alabama6 trials

A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors

Research Site

Phase 1
A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors

Children's Hospital of Alabama/UAB

Phase 2
Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial

University of Alabama at Birmingham Cancer Center

Phase 2
Metastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomes

University of Alabama at Birmingham (Children's of Alabama)

Phase 1
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

University of Alabama at Birmingham Cancer Center

Phase 1
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial

University of Alabama at Birmingham Cancer Center

Phase 2

Houston, Texas3 trials

A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases

M D Anderson Cancer Center

Phase 2
Atezolizumab and Cabozantinib for the Treatment of Recurrent Glioblastoma

M D Anderson Cancer Center

Phase 1/2
Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC

MD Anderson Cancer Center

Phase 1/2

La Jolla, California2 trials

Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer

University of California San Diego

Phase 2
Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer

UC San Diego Moores Cancer Center

Phase 2

Huntsville, Alabama1 trial

Pan Tumor Rollover Study

Local Institution - 0220

Phase 2

Anchorage, Alaska1 trial

Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer

Anchorage Associates in Radiation Medicine

Phase 3

Gilbert, Arizona1 trial

Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma

Research Site

Phase 3

Phoenix, Arizona1 trial

KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors

Mayo Clinic Comprehensive Cancer Center

Phase 1

Scottsdale, Arizona1 trial

Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer

Mayo Clinic in Arizona

Phase 2

Duarte, California1 trial

Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study

City of Hope National Medical Center

Phase 2

Orange, California1 trial

Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular Carcinoma

Chao Family Comprehensive Cancer Center, University of California, Irvine

Phase 2

San Francisco, California1 trial

Cabozantinib With Ifosfamide in Relapsed/Refractory Sarcomas

University of California San Francisco

Phase 1

New Haven, Connecticut1 trial

A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)

Local Institution - 0117

Phase 1/2

Miami, Florida1 trial

Cabozantinib for Patients With Recurrent or Progressive Meningioma

Miami Cancer Institute at Baptist Health, Inc.

Phase 2

Chicago, Illinois1 trial

A Pilot Phase II Study of Maintenance Cabozantinib Plus Pembrolizumab for Patients With Metastatic Squamous Non-Small Cell Lung Cancer (sqNSCLC)

Ryan Nguyen

Phase 2

Westwood, Kansas1 trial

Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies

University of Kansas Cancer Center

Phase 1/2

Baltimore, Maryland1 trial

A Study of Abemaciclib and Cabozantinib in People With Clear Cell Renal Cell Carcinoma (ccRCC)

Johns Hopkins University (Data Collection Only)

Phase 1/2

Boston, Massachusetts1 trial

Atezolizumab and Cabozantinib for the Treatment of Adolescents and Young Adults With Recurrent or Metastatic Osteosarcoma, TACOS Study

Dana-Farber Cancer Institute

Phase 2

Detroit, Michigan1 trial

Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)

Karmanos Cancer Center ( Site 0108)

Phase 3

Basking Ridge, New Jersey1 trial

Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity

Memorial Sloan Kettering Basking Ridge

Phase 2

New Brunswick, New Jersey1 trial

CYTO Reductive Surgery in Kidney Cancer Plus Immunotherapy and Targeted Kinase Inhibition

The Rutgers Cancer Institute of New Jersey

Phase 2

New York, New York1 trial

Rapid Sequencing of Approved Therapies in Patients with Metastatic or Unresectable Clear Cell Renal Cell Carcinoma

Icahn School of Medicine at Mount Sinai

Early 1

Philadelphia, Pennsylvania1 trial

Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors

Fox Chase Cancer Center

Phase 2

Pittsburgh, Pennsylvania1 trial

Autologous Dendritic Cell Vaccine in Kidney Cancer

UPMC Department of Urology

Phase 2

Salt Lake City, Utah1 trial

Dose-Escalation Study of Cabozantinib in Combination With Lutetium-177 (177Lu)-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer

Huntsman Cancer Institute at University of Utah

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.